354 related articles for article (PubMed ID: 19369348)
1. Cytotoxic-T-lymphocyte-mediated elimination of target cells transduced with engineered adeno-associated virus type 2 vector in vivo.
Li C; Hirsch M; DiPrimio N; Asokan A; Goudy K; Tisch R; Samulski RJ
J Virol; 2009 Jul; 83(13):6817-24. PubMed ID: 19369348
[TBL] [Abstract][Full Text] [Related]
2. Cross-presentation of adeno-associated virus serotype 2 capsids activates cytotoxic T cells but does not render hepatocytes effective cytolytic targets.
Wang L; Figueredo J; Calcedo R; Lin J; Wilson JM
Hum Gene Ther; 2007 Mar; 18(3):185-94. PubMed ID: 17324107
[TBL] [Abstract][Full Text] [Related]
3. Adeno-associated virus type 2 (AAV2) capsid-specific cytotoxic T lymphocytes eliminate only vector-transduced cells coexpressing the AAV2 capsid in vivo.
Li C; Hirsch M; Asokan A; Zeithaml B; Ma H; Kafri T; Samulski RJ
J Virol; 2007 Jul; 81(14):7540-7. PubMed ID: 17475652
[TBL] [Abstract][Full Text] [Related]
4. Kinetics of adeno-associated virus serotype 2 (AAV2) and AAV8 capsid antigen presentation in vivo are identical.
He Y; Weinberg MS; Hirsch M; Johnson MC; Tisch R; Samulski RJ; Li C
Hum Gene Ther; 2013 May; 24(5):545-53. PubMed ID: 23534873
[TBL] [Abstract][Full Text] [Related]
5. Cytotoxic T lymphocyte responses to transgene product, not adeno-associated viral capsid protein, limit transgene expression in mice.
Siders WM; Shields J; Kaplan J; Lukason M; Woodworth L; Wadsworth S; Scaria A
Hum Gene Ther; 2009 Jan; 20(1):11-20. PubMed ID: 18828728
[TBL] [Abstract][Full Text] [Related]
6. Pre-existing AAV capsid-specific CD8+ T cells are unable to eliminate AAV-transduced hepatocytes.
Li H; Murphy SL; Giles-Davis W; Edmonson S; Xiang Z; Li Y; Lasaro MO; High KA; Ertl HC
Mol Ther; 2007 Apr; 15(4):792-800. PubMed ID: 17245353
[TBL] [Abstract][Full Text] [Related]
7. Determination of specific CD4 and CD8 T cell epitopes after AAV2- and AAV8-hF.IX gene therapy.
Chen J; Wu Q; Yang P; Hsu HC; Mountz JD
Mol Ther; 2006 Feb; 13(2):260-9. PubMed ID: 16324888
[TBL] [Abstract][Full Text] [Related]
8. Engineered AAV vector minimizes in vivo targeting of transduced hepatocytes by capsid-specific CD8+ T cells.
Martino AT; Basner-Tschakarjan E; Markusic DM; Finn JD; Hinderer C; Zhou S; Ostrov DA; Srivastava A; Ertl HC; Terhorst C; High KA; Mingozzi F; Herzog RW
Blood; 2013 Mar; 121(12):2224-33. PubMed ID: 23325831
[TBL] [Abstract][Full Text] [Related]
9. Application of polyploid adeno-associated virus vectors for transduction enhancement and neutralizing antibody evasion.
Chai Z; Sun J; Rigsbee KM; Wang M; Samulski RJ; Li C
J Control Release; 2017 Sep; 262():348-356. PubMed ID: 28789965
[TBL] [Abstract][Full Text] [Related]
10. Capsid antigen presentation flags human hepatocytes for destruction after transduction by adeno-associated viral vectors.
Pien GC; Basner-Tschakarjan E; Hui DJ; Mentlik AN; Finn JD; Hasbrouck NC; Zhou S; Murphy SL; Maus MV; Mingozzi F; Orange JS; High KA
J Clin Invest; 2009 Jun; 119(6):1688-95. PubMed ID: 19436115
[TBL] [Abstract][Full Text] [Related]
11. Induction of immunity to antigens expressed by recombinant adeno-associated virus depends on the route of administration.
Brockstedt DG; Podsakoff GM; Fong L; Kurtzman G; Mueller-Ruchholtz W; Engleman EG
Clin Immunol; 1999 Jul; 92(1):67-75. PubMed ID: 10413654
[TBL] [Abstract][Full Text] [Related]
12. Adeno-associated virus capsid antigen presentation is dependent on endosomal escape.
Li C; He Y; Nicolson S; Hirsch M; Weinberg MS; Zhang P; Kafri T; Samulski RJ
J Clin Invest; 2013 Mar; 123(3):1390-401. PubMed ID: 23454772
[TBL] [Abstract][Full Text] [Related]
13. Inhibition of antigen presentation during AAV gene therapy using virus peptides.
Shao W; Chen X; Samulski RJ; Hirsch ML; Li C
Hum Mol Genet; 2018 Feb; 27(4):601-613. PubMed ID: 29272432
[TBL] [Abstract][Full Text] [Related]
14. Efficient Capsid Antigen Presentation From Adeno-Associated Virus Empty Virions
Pei X; Earley LF; He Y; Chen X; Hall NE; Samulski RJ; Li C
Front Immunol; 2018; 9():844. PubMed ID: 29725339
[TBL] [Abstract][Full Text] [Related]
15. Undetectable transcription of cap in a clinical AAV vector: implications for preformed capsid in immune responses.
Hauck B; Murphy SL; Smith PH; Qu G; Liu X; Zelenaia O; Mingozzi F; Sommer JM; High KA; Wright JF
Mol Ther; 2009 Jan; 17(1):144-52. PubMed ID: 18941440
[TBL] [Abstract][Full Text] [Related]
16. Cellular immune response to cryptic epitopes during therapeutic gene transfer.
Li C; Goudy K; Hirsch M; Asokan A; Fan Y; Alexander J; Sun J; Monahan P; Seiber D; Sidney J; Sette A; Tisch R; Frelinger J; Samulski RJ
Proc Natl Acad Sci U S A; 2009 Jun; 106(26):10770-4. PubMed ID: 19541644
[TBL] [Abstract][Full Text] [Related]
17. Adeno-associated virus capsid structure drives CD4-dependent CD8+ T cell response to vector encoded proteins.
Mays LE; Vandenberghe LH; Xiao R; Bell P; Nam HJ; Agbandje-McKenna M; Wilson JM
J Immunol; 2009 May; 182(10):6051-60. PubMed ID: 19414756
[TBL] [Abstract][Full Text] [Related]
18. Proteasome inhibitors decrease AAV2 capsid derived peptide epitope presentation on MHC class I following transduction.
Finn JD; Hui D; Downey HD; Dunn D; Pien GC; Mingozzi F; Zhou S; High KA
Mol Ther; 2010 Jan; 18(1):135-42. PubMed ID: 19904235
[TBL] [Abstract][Full Text] [Related]
19. Vector uncoating limits adeno-associated viral vector-mediated transduction of human dendritic cells and vector immunogenicity.
Rossi A; Dupaty L; Aillot L; Zhang L; Gallien C; Hallek M; Odenthal M; Adriouch S; Salvetti A; Büning H
Sci Rep; 2019 Mar; 9(1):3631. PubMed ID: 30842485
[TBL] [Abstract][Full Text] [Related]
20. CD8+ T cell recognition of epitopes within the capsid of adeno-associated virus 8-based gene transfer vectors depends on vectors' genome.
Wu TL; Li H; Faust SM; Chi E; Zhou S; Wright F; High KA; Ertl HC
Mol Ther; 2014 Jan; 22(1):42-51. PubMed ID: 24077034
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
